News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Active Biotech AB (BTPC) Interim Report January - March 2013


4/25/2013 9:09:42 AM

LUND, SWEDEN--(Marketwired - April 25, 2013) -


Laquinimod

· first patient enrolled in CONCERTO, the third Phase III placebo-controlled study for the treatment of relapsing-remitting multiple sclerosis

· data presented at AAN showed reduced disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared with delayed treatment

Tasquinimod

· the Phase III study is proceeding according to plan

ANYARA

· Phase II/III study in renal cell cancer concluded

· Results presented:

- study did not achieve primary clinical endpoint

- doubling of progression-free survival and overall survival in 25 percent of patients

- planning of the continued clinical development ongoing

57-57 (paquinimod)

· clinical trial in systemic sclerosis concluded, evaluation underway

ISI

· focus on submission of patents

Other information

· Active Biotech raised SEK 270 M through a directed share issue to Investor

                                      Jan - Mar       Jan - Dec

  (SEK M)                           2013    2012      2012
---------------------------------------------------------------
   *      Net sales                  2.4      2.6      227.9

   *      Operating loss             -77.0    -100.7   -163.2

   *      Net loss                   -78.0    -99.0    -175.0

   *      Earnings per share (SEK)   -1.10    -1.44    -2.54


This report is also available at www.activebiotech.com

Active Biotech AB : Interim Report January - March 2013: http://hugin.info/1002/R/1695994/558366.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1695994]


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Hans Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB Corp. Reg. No. 556223-9227)
Box 724, SE-220 07
Lund
Tel: 046 (0)46-19 20 00
Fax: +46 (0)46-19 11 00


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES